Abstract | INTRODUCTION: AREA COVERED: The article covers novel strategies, using either small molecules or monoclonal antibodies. These strategies include: approaches targeting IKK-b- NF-kB ( salicylates, salsalate), TNF-α ( etanercept, infliximab, adalimumab), IL-1β ( anakinra, canakinumab) and IL-6 ( tocilizumab), AMP-activated protein kinase activators, sirtuin-1 activators, mammalian target of rapamycin inhibitors and C-C motif chemokine receptor 2 antagonists. EXPERT OPINION: The available data supports the concept that targeting inflammation improves insulin sensitivity and β-cell function; it also ameliorates glucose control in insulin-resistant patients with inflammatory rheumatoid diseases as well in patients with metabolic syndrome or T2DM. Although promising, the observed metabolic effects remain rather modest in most clinical trials. The potential use of combined anti-inflammatory agents targeting both insulin resistance and insulin secretion appears appealing but remains unexplored. Large-scale prospective clinical trials are underway to investigate the safety and efficacy of different anti-inflammatory drugs. Further evidence is needed to support the concept that targeting inflammation pathways may represent a valuable option to tackle the cardiometabolic complications of obesity.
|
Authors | Nathalie Esser, Nicolas Paquot, André J Scheen |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 24
Issue 3
Pg. 283-307
(Mar 2015)
ISSN: 1744-7658 [Electronic] England |
PMID | 25345753
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Inflammatory Agents
- Insulin
|
Topics |
- Animals
- Anti-Inflammatory Agents
(pharmacology, therapeutic use)
- Cardiovascular Diseases
(drug therapy, physiopathology, prevention & control)
- Diabetes Mellitus, Type 2
(drug therapy, physiopathology, prevention & control)
- Drug Design
- Humans
- Inflammation
(complications, drug therapy)
- Insulin
(metabolism)
- Insulin Resistance
- Metabolic Syndrome
(drug therapy, physiopathology, prevention & control)
- Obesity
(complications, drug therapy, physiopathology)
|